Highlights:
- The protected provide of psychedelic drug merchandise manufactured at a GMP-level is crucial in treating severe psychological well being points. Minister of Mental Health and Addictions, the Honourable Carolyn Bennett, has publicly acknowledged that protected drug provide is paramount to decreasing overdose deaths.
- Optimi Health is the most important cultivator of pure EU-GMP psilocybin and MDMA in North America.
- Optimi Health is licensed by Health Canada to provide medical trials and sufferers permitted underneath the Special Access Program.
VANCOUVER, British Columbia, Oct. 06, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a number one Canadian-based firm licensed by Health Canada to supply and provide pure, EU-GMP grade psilocybin and different psychedelic substances, most notably MDMA, is applauding the federal government of Alberta’s resolution to control some psychedelics for therapeutic use within the province.
The proposed framework as acknowledged by the Government of Alberta comes into impact on January 16, 2023. It would give a doctor, psychiatrist, or physician the flexibility to prescribe and administer psilocybin, MDMA, or different psychedelics produced by Optimi to sufferers underneath the Mental Health Services Protection Act.
Optimi CEO, Bill Ciprick, made the next assertion on behalf of the Company:
“Yesterday, the Government of Alberta made a bold and politically courageous decision to regulate the use of psychedelic therapy for patients suffering from a variety of treatment-resistant conditions. They have accepted the substantial body of research, including the completion of a growing number of randomized clinical trials, which highlight psilocybin (the active ingredient in “magic” mushrooms) when paired with psychotherapy as an rising and novel strategy for the remedy of a number of psychological well being circumstances, together with treatment-resistant melancholy, substance-use dysfunction, and extreme anxiousness related to a terminal prognosis.
Thanks to Optimi’s current partnerships and provide agreements with clinics, therapists, and researchers inside the Province of Alberta — together with ATMA Journey Centers, Bloom Psychedelic Therapy and Research Centre, and SABI Mind — the Company is uniquely positioned to help the event of Alberta’s regulated psychedelic remedy infrastructure.
The growing proof supporting the advantages of psilocybin-containing mushrooms when used as a part of psychotherapy has resulted in rising worldwide curiosity in transferring shortly to extend affected person entry to this remedy given the spectacular and rising monitor information of security in each the therapeutic and naturalistic use contexts.
We have seen widespread, bi-partisan help for psilocybin and MDMA Bills launched in State legislatures throughout the United States; the Biden Administration has appointed a particular process power to know and put together for the regulation of psychedelics within the U.S; and lately, Canadian Minister of Mental Health and Addictions, the Honourable Carolyn Bennett, admitted that Canada wants a protected provide of medicine to battle the spiraling opioid disaster.
While we await additional particulars on Alberta’s regulatory framework, we encourage different provincial well being ministries to start out asking the proper questions on psychedelic remedy, and to hunt additional steering from the Psychedelic Association of Canada’s Memorandum of Regulatory Analysis (MORA) which supplies a step-by-step regulatory framework for end-of-life and palliative Canadians.
As a Health Canada licensed provider of EU-GMP pure psilocybin and artificial psychedelics, Optimi Health is dedicated to working with the Government of Alberta to provide the therapeutic psychedelics they should deal with those that are struggling.”
Optimi’s state-of-the-art EU-GMP cultivation and analytical services in Princeton, British Columbia are actually absolutely operational. After finishing the most important authorized develop of pure psilocybin in Canada’s historical past, the Company is aiming for first-mover benefit in Oregon because the demand for pure product intensifies within the legalized State and will likely be contacting the federal government of Alberta within the coming days to debate provide.
“We believe a key differentiator in the psychedelics space is that Optimi is commercializing and ready to go now,” stated Dane Stevens, Optimi Co-Founder and Chief Marketing Officer. “While we eagerly wait for Health Canada to regulate access for something we believe to be a safe and efficacious medicine when delivered with therapy, this announcement by the Government of Alberta can help patients today. Optimi’s timeline is now, and we are excited to be one of the first company’s supplying tested, EU-GMP psychedelic products to regulated jurisdictions such as Oregon and Alberta,” added Stevens.
More info on the regulatory administrative and repair necessities proposed underneath Alberta’s Mental Health Services Protection Act might be discovered right here.
FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:
Michael Kydd
Investor Relations
Email: [email protected]
Phone: +1 (902) 880 6121
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)
Optimi Health Corp. is a Canadian-based firm licensed by Health Canada to supply and provide pure, EU-GMP grade psilocybin and artificial psychedelic substances, in addition to purposeful mushrooms that concentrate on the well being and wellness markets. Built with the aim of manufacturing scalable psychedelic formulations for transformational human experiences, the Company’s objective is to be the primary trusted, compassionate provider of protected drug merchandise all through the world. Optimi’s merchandise are grown at its two services comprising a complete of 20,000 sq. toes in Princeton, British Columbia, making it the most important psilocybin and MDMA cultivator in North America.
FORWARD‐LOOKING STATEMENTS
This information launch incorporates ahead‐trying statements and ahead‐trying info inside the that means of Canadian securities laws (collectively, “forward‐looking statements”) that relate to Optimi’s present expectations and views of future occasions. Any statements that categorical, or contain discussions as to, expectations, beliefs, plans, targets, assumptions or future occasions or efficiency (usually, however not all the time, by means of using phrases or phrases equivalent to “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) will not be historic details and could also be ahead‐trying statements and will contain estimates, assumptions and uncertainties which may trigger precise outcomes or outcomes to vary materially from these expressed in such ahead‐trying statements. No assurance might be on condition that these expectations will show to be right and such ahead‐trying statements included on this information launch shouldn’t be unduly relied upon. These statements converse solely as of the date of this information launch. In explicit and with out limitation, this information launch incorporates ahead‐ trying statements pertaining to actions proposed to be carried out underneath the Company’s permitted Health Canada vendor’s licence and related business associated to Psilocybin, Psilocin, different psychedelic substances, some being synthetically formulated, and Optimi’s plans, focus and targets.
Forward‐trying statements are primarily based on various assumptions and are topic to various dangers and uncertainties, a lot of that are past Optimi’s management, which may trigger precise outcomes and occasions to vary materially from these which are disclosed in or implied by such ahead‐trying statements. Such dangers and uncertainties embrace, however will not be restricted to, the affect and development of the COVID‐19 pandemic and different components set forth underneath “Forward‐Looking Statements” and “Risk Factors” within the Company’s Annual info Form dated January 12, 2022, and different steady disclosure filings accessible underneath Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to replace or revise any ahead‐trying statements, whether or not on account of new info, future occasions or in any other case, besides as could also be required by regulation. New components emerge every so often, and it’s not doable for Optimi to foretell all of them or assess the affect of every such issue or the extent to which any issue, or mixture of things, might trigger outcomes to vary materially from these contained in any ahead‐trying assertion.
Any ahead‐trying statements contained on this information launch are expressly certified of their entirety by this cautionary assertion.
